

Special Issue

Advances in Colorectal Cancer: An Emerging Personalized Therapeutic Opportunity

Message from the Guest Editors

Colorectal cancer (CRC) is one of the most common malignant tumors worldwide. The cumulative findings of the past years demonstrate the existence of different pathways involved in CRC origin and progression. Due to the heterogeneity of CRC, surgery, chemotherapy, and radiation are ineffective in all cases. The integration of artificial intelligence algorithms into studies linking CRC to diagnosis and therapy will greatly enhance our understanding of the effects of individual-based cancer care. Furthermore, CRC treatment is entering a new era with robotic surgery and novel computer-assisted drug delivery techniques. This Special Issue aims to highlight the advantages and limitations of personalized medicine in CRC therapy. Studies include those that explore current scenarios of personalized medicine and the challenges faced in different countries. Finally, we encourage debates on the future perspectives of personalized medicine in CRC and how it could be integrated into the healthcare system.

Guest Editors

Dr. Alberto Vannelli

Department of Surgery, Valduce Hospital, Como, Italy

Dr. Tommaso A. Dragani

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Deadline for manuscript submissions

16 December 2024



Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/si/187405

*Journal of Personalized
Medicine*
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).